Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
October 15, 2024 6:19 AM EDTWells Fargo analyst Derek Archila reiterated an Overweight rating and $32.00 price target on Nurix (NASDAQ: NRIX)
The analyst comments "Thoughts on the stock. Shares are up +146% vs XBI's +10% YTD. While there is decent value priced in for NX-5948's oppty... More
